Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jonathan Port to Humans

This is a "connection" page, showing publications Jonathan Port has written about Humans.

 
Connection Strength
 
 
 
0.078
 
  1. Port JD, Sucharov C. Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials. J Cardiovasc Pharmacol. 2010 Nov; 56(5):444-53.
    View in: PubMed
    Score: 0.010
  2. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol. 2008 Aug; 45(2):185-92.
    View in: PubMed
    Score: 0.009
  3. David PS, Tanveer R, Port JD. FRET-detectable interactions between the ARE binding proteins, HuR and p37AUF1. RNA. 2007 Sep; 13(9):1453-68.
    View in: PubMed
    Score: 0.008
  4. Blaxall BC, Pende A, Wu SC, Port JD. Correlation between intrinsic mRNA stability and the affinity of AUF1 (hnRNP D) and HuR for A+U-rich mRNAs. Mol Cell Biochem. 2002 Mar; 232(1-2):1-11.
    View in: PubMed
    Score: 0.006
  5. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001 May; 33(5):887-905.
    View in: PubMed
    Score: 0.005
  6. Blaxall BC, Pellett AC, Wu SC, Pende A, Port JD. Purification and characterization of beta-adrenergic receptor mRNA-binding proteins. J Biol Chem. 2000 Feb 11; 275(6):4290-7.
    View in: PubMed
    Score: 0.005
  7. Blaxall BC, Port JD. Determination of mRNA stability and characterization of proteins interacting with adrenergic receptor mRNAs. Methods Mol Biol. 2000; 126:453-65.
    View in: PubMed
    Score: 0.005
  8. Mitchusson KD, Blaxall BC, Pende A, Port JD. Agonist-mediated destabilization of human beta1-adrenergic receptor mRNA: role of the 3' untranslated translated region. Biochem Biophys Res Commun. 1998 Nov 18; 252(2):357-62.
    View in: PubMed
    Score: 0.004
  9. Bristow M, Port JD. Beta-adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl. 1998; 47:45-55.
    View in: PubMed
    Score: 0.004
  10. Pende A, Tremmel KD, DeMaria CT, Blaxall BC, Minobe WA, Sherman JA, Bisognano JD, Bristow MR, Brewer G, Port J. Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J Biol Chem. 1996 Apr 05; 271(14):8493-501.
    View in: PubMed
    Score: 0.004
  11. Lindenfeld J, Cleveland JC, Kao DP, White M, Wichman S, Bristow JC, Peterson V, Rodegheri-Brito J, Korst A, Blain-Nelson P, Sederberg J, Hunt SA, Gilbert EM, Ambardekar AV, Minobe W, Port JD, Bristow MR. Sex-related differences in age-associated downregulation of human ventricular myocardial ?1-adrenergic receptors. J Heart Lung Transplant. 2016 Mar; 35(3):352-361.
    View in: PubMed
    Score: 0.004
  12. Hinterberg MA, Kao DP, Bristow MR, Hunter LE, Port JD, G?rg C. Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput. 2015; 419-30.
    View in: PubMed
    Score: 0.003
  13. Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
    View in: PubMed
    Score: 0.003
  14. Bristow MR, Larrabee P, M?ller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
    View in: PubMed
    Score: 0.003
  15. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010 Jan; 3(1):21-8.
    View in: PubMed
    Score: 0.002
  16. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, Bristow MR. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation. 1997 Mar 04; 95(5):1193-200.
    View in: PubMed
    Score: 0.001
  17. White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, Hammond E, Abraham WT, Wolfel EE, Lindenfeld J, et al. Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage. Circulation. 1995 Oct 15; 92(8):2183-9.
    View in: PubMed
    Score: 0.001
  18. Farrukh HM, White M, Port JD, Handwerger D, Larrabee P, Klein J, Roden RA, Skerl L, Renlund DG, Feldman AM, et al. Up-regulation of beta 2-adrenergic receptors in previously transplanted, denervated nonfailing human hearts. J Am Coll Cardiol. 1993 Dec; 22(7):1902-8.
    View in: PubMed
    Score: 0.001
  19. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993 Dec; 92(6):2737-45.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)